- Home
- CDXS
CDXS
Codexis Inc.
as 03-28-2025 4:00pm EST
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 230.3M | IPO Year: | 2010 |
| Target Price: | $11.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.43 - $6.08 | Next Earning Date: | 05-01-2025 |
| Revenue: | $59,345,000 | Revenue Growth: | -15.39% |
| Revenue Growth (this year): | 14.56% | Revenue Growth (next year): | 21.41% |
Stock Insider Trading Activity of Codexis Inc. (CDXS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | CDXS | 10% Owner | Mar 20 '25 | Buy | $2.54 | 92,923 | $236,266.02 | 9,250,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Mar 13 '25 | Buy | $2.54 | 85,000 | $216,155.00 | 9,250,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Mar 6 '25 | Buy | $2.61 | 100,000 | $261,350.00 | 9,250,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Mar 4 '25 | Buy | $2.67 | 65,000 | $172,273.00 | 9,250,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Feb 28 '25 | Buy | $2.90 | 195,000 | $574,340.43 | 9,250,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Feb 10 '25 | Buy | $4.10 | 50,000 | $205,481.50 | 9,250,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Jan 30 '25 | Buy | $4.39 | 65,000 | $282,967.00 | 9,250,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Dec 30 '24 | Buy | $4.68 | 45,000 | $210,994.50 | 9,250,000 |
Latest Codexis Inc. News
CDXS Breaking Stock News: Dive into CDXS Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Codexis Signs First Contract for ECO Synthesis Manufacturing Services
GlobeNewswire
4 days ago
Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services
GlobeNewswire
21 days ago
Codexis Announces New Employment Inducement Grants
Simply Wall St.
a month ago
When Will Codexis, Inc. (NASDAQ:CDXS) Become Profitable?
Thomson Reuters StreetEvents
a month ago
Q4 2024 Codexis Inc Earnings Call
GuruFocus.com
a month ago
Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ...
Zacks
a month ago
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates
Associated Press Finance
a month ago
Codexis: Q4 Earnings Snapshot
Compare CDXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDXS Codexis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.